Low-dose doxepin for the treatment of insomnia: emerging data

Bibliography

• Krystal AD. Treating the health, quality of life, and functional impairments in insomnia. J Clin Sleep Med 2007;3:63-72
   PubMed Web of Science ®Google Scholar
• Roth T, Roehrs T. Insomnia: epidemiology, characteristics, and consequences. Clin Cornerstone 2003;5:5-15
   PubMedGoogle Scholar
• Foley DJ, Monjan A, Simonsick EM, et al. Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6,800 persons over three years. Sleep 1999;22(Suppl 2):S366-72
   PubMed Web of Science ®Google Scholar
• Foley DJ, Monjan AA, Brown SL, et al. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep 1995;18:425-32
   PubMed Web of Science ®Google Scholar
• Doghramji K. The epidemiology and diagnosis of insomnia. Am J Manag Care 2006;12(8 Suppl):S214-20
   PubMed Web of Science ®Google Scholar
• Newman AB, Enright PL, Manolio TA, et al. Sleep disturbance, psychosocial correlates, and cardiovascular disease in 5201 older adults: the Cardiovascular Health Study. J Am Geriatr Soc 1997;45:1-7
   PubMed Web of Science ®Google Scholar
• Owens JF, Matthews KA. Sleep disturbance in healthy middle-aged women. Maturitas 1998;30:41-50
   PubMed Web of Science ®Google Scholar
• Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996;39:411-18
   PubMed Web of Science ®Google Scholar
• Hohagen F, Rink K, Kappler C, et al. Prevalence and treatment of insomnia in general practice. A longitudinal study. Eur Arch Psychiatry Clin Neurosci 1993;242:329-36
   PubMed Web of Science ®Google Scholar
• Franzen PL, Buysse DJ. Sleep disturbances and depression: risk relationships for subsequent depression and therapeutic implications. Dialogues Clin Neurosci 2008;10:473-81
   PubMedGoogle Scholar
• Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6:97-111
   PubMed Web of Science ®Google Scholar
• Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006;59:1052-60
   PubMed Web of Science ®Google Scholar
• Krystal A, Fava M, Rubens R, et al. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. J Clin Sleep Med 2007;3:48-55
   PubMed Web of Science ®Google Scholar
• Singh H, Becker PM. Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs 2007;16:1295-305
   PubMed Web of Science ®Google Scholar
• Pollack M, Kinrys G, Krystal A, et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 2008;65:551-62
   PubMed Web of Science ®Google Scholar
• Pfizer. SINEQUAN® (doxepin HCl) CAPSULES ORAL CONCENTRATE. 2008
   Google Scholar
• Epstein JB, Truelove EL, Oien H, et al. Oral topical doxepin rinse: anesthetic effect in normal subjects. Pain Res Manag 2003;8:195-7
   PubMedGoogle Scholar
• McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. Br J Clin Pharmacol 2000;49:574-9
   PubMed Web of Science ®Google Scholar
• Sabroe RA, Kennedy CT, Archer CB. The effects of topical doxepin on responses to histamine, substance P and prostaglandin E2 in human skin. Br J Dermatol 1997;137:386-90
   PubMed Web of Science ®Google Scholar
• Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 2007;30:1555-61
   PubMed Web of Science ®Google Scholar
• Scharf M, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2008;69:1557-64
   PubMed Web of Science ®Google Scholar
• Pinder RM, Brogden RN, Speight TM, Avery GS. Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression. Drugs 1977;13:161-218
   PubMed Web of Science ®Google Scholar
• Finnerty RJ, Goldberg HL. Specific responses to imipramine and doxepin in psychoneurotic depressed patients with sleep disturbance. J Clin Psychiatry 1981;42:275-9
   PubMed Web of Science ®Google Scholar
• Roth T, Zorick F, Wittig R, et al. The effects of doxepin HCl on sleep and depression. J Clin Psychiatry 1982;43:366-8
   PubMed Web of Science ®Google Scholar
• Fann WE, Cavanaugh JH, Kaufmann JS, et al. Doxepin: effects on transport of biogenic amines in man. Psychopharmacologia 1971;22:111-25
   PubMed Web of Science ®Google Scholar
• Horn AS. The interactions of tricyclic antidepressants with the biogenic amine uptake systems in the central nervous system. Postgrad Med J 1976;52(3 Suppl):25-32
   PubMed Web of Science ®Google Scholar
• Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999;19:467-89
   PubMed Web of Science ®Google Scholar
• Ishikawa K, Shibanoki S, Kubo T, et al. Effects of various tricyclic antidepressants on amine uptake. Eur J Pharmacol 1986;120:63-8
   PubMed Web of Science ®Google Scholar
• Tashiro M, Mochizuki H, Iwabuchi K, et al. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci 2002;72:409-14
   PubMed Web of Science ®Google Scholar
• Tashiro M, Duan X, Kato M, et al. Brain histamine H1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with 11C-doxepin. Br J Clinical Pharmacol 2008;65:811-21
   PubMed Web of Science ®Google Scholar
• Yanai K, Tashiro M. The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies. Pharmacol Ther 2007;113:1-15
   PubMed Web of Science ®Google Scholar
• Koski A, Ojanpera I, Sistonen J, et al. A fatal doxepin poisoning associated with a defective CYP2D6 genotype. Am J Forensic Med Pathol 2007;28:259-61
   PubMed Web of Science ®Google Scholar
• Gregor KJ, Way K, Young CH, James SP. Concomitant use of selective serotonin reuptake inhibitors with other cytochrome P450 2D6 or 3A4 metabolized medications: how often does it really happen? J Affect Disord 1997;46:59-67
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet 2001;40:753-72
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin pharmacokinet 2000;38:111-80
   PubMed Web of Science ®Google Scholar
• Hajak G, Rodenbeck A, Adler L, et al. Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Pharmacopsychiatry 1996;29:187-92
   PubMed Web of Science ®Google Scholar
• Rodenbeck A, Cohrs S, Jordan W, et al. The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks. Psychopharmacology 2003;170:423-8
   PubMed Web of Science ®Google Scholar
• Hajak G, Rodenbeck A, Voderholzer U, et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry 2001;62:453-63
   PubMed Web of Science ®Google Scholar
• Biggs JT, Spiker DG, Petit JM, Ziegler VE. Tricyclic antidepressant overdose: incidence of symptoms. JAMA 1977;238:135-8
   PubMed Web of Science ®Google Scholar
• Harrigan RA, Brady WJ. ECG abnormalities in tricyclic antidepressant ingestion. Am J Emerg Med 1999;17:387-93
   PubMed Web of Science ®Google Scholar
• Tobis JM, Aronow WS. Cardiotoxicity of amitriptyline and doxepin. Clin Pharmacol Ther 1981;29:359-64
   PubMed Web of Science ®Google Scholar
• Buckley NA, Dawson AH, Whyte IM, Henry DA. Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet 1994;343:159-62
   PubMed Web of Science ®Google Scholar
• Bailey DN. Effect of pH changes and ethanol on the binding of tricyclic antidepressants to cholestyramine in simulated gastric fluid. Ther Drug Monit 1992;14:343-6
   PubMed Web of Science ®Google Scholar
• Janson PA, Watt JB, Hermos JA. Doxepin overdose. Success with physostigmine and failure with neostigmine in reversing toxicity. JAMA 1977;237:2632-3
   PubMed Web of Science ®Google Scholar
• Kerr GW, McGuffie AC, Wilkie S. Tricyclic antidepressant overdose: a review. Emerg Med J 2001;18:236-41
   PubMed Web of Science ®Google Scholar
• Samaxon Press Release. Available from: http://www.somaxon.com/media/pdf/press2009/SOMX_FDA_update_4-7-09.pdf [Last accessed 14 April 2009]
   Google Scholar